{"id":5910,"date":"2011-01-11T16:29:54","date_gmt":"2011-01-11T21:29:54","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?p=5910"},"modified":"2011-07-19T17:44:39","modified_gmt":"2011-07-19T21:44:39","slug":"candesartan-beats-losartan-in-swedish-hf-registry","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2011\/01\/11\/candesartan-beats-losartan-in-swedish-hf-registry\/","title":{"rendered":"Candesartan Beats Losartan in Swedish HF Registry"},"content":{"rendered":"<p>The Swedish Heart Failure Registry followed more than 5,000 patients treated with the angiotensin II receptor blockers (ARBs) candesartan or losartan between 2000 and 2009. According to a <a href=\"http:\/\/jama.ama-assn.org\/content\/305\/2\/175.abstract?sid=c3a5d1f8-0d00-4f23-bee2-6aa8b0b723c1\">paper published in <em>JAMA<\/em><\/a>, survival at one year was 90% in the candesartan group compared to 83% in the losartan group. Five-year survival was 61% and 44%. After adjustment for clinical differences and propensity scores, the hazard ratio for losartan compared to candesartan was 1.43.<\/p>\n<p>Discussing the large difference between the drugs, the authors acknowledge that &#8220;the magnitude of our findings may be due to chance, but RCTs may understate &#8216;real world&#8217; differences, and it is conceivable that candesartan is better than losartan by a magnitude similar to placebo.&#8221; \u00a0They conclude, however, that &#8220;clinical decision making should await supportive evidence&#8221; and recommend that differences between ARBs should be tested in randomized trials, though they acknowledge it may be more feasible to confirm the finding in other registries.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Swedish Heart Failure Registry followed more than 5,000 patients treated with the angiotensin II receptor blockers (ARBs) candesartan or losartan between 2000 and 2009. According to a paper published in JAMA, survival at one year was 90% in the candesartan group compared to 83% in the losartan group. Five-year survival was 61% and 44%. [&hellip;]<\/p>\n","protected":false},"author":196,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[14],"tags":[647,648,649],"class_list":["post-5910","post","type-post","status-publish","format-standard","hentry","category-heart-failure","tag-arbs","tag-candesartan","tag-losartan"],"_links":{"self":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/5910","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/users\/196"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/comments?post=5910"}],"version-history":[{"count":0,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/posts\/5910\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/media?parent=5910"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/categories?post=5910"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.nejm.org\/cardioexchange\/wp-json\/wp\/v2\/tags?post=5910"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}